📣 VC round data is live. Check it out!
- Public Comps
- Meta Biomed
Meta Biomed Valuation Multiples
Discover revenue and EBITDA valuation multiples for Meta Biomed and similar public comparables like Cyclopharm, Senzime, FluoGuide, Optiscan Imaging and more.
Meta Biomed Overview
About Meta Biomed
Meta Biomed Co Ltd manufactures and markets suture and dental supplies. The company's dental products include endodontic materials, restorative materials, and bone graft material, as well as equipment, including Endo motor, and Endo System. It also offers suture products comprising multifilament and monofilament products, as well as orthopedics and incontinence meshs; bone products consisting of bone substitutes and cement; and medical products, including endoscope and ultrasonic products.
Founded
1999
HQ

Employees
N/A
Website
Sectors
Financials (FY)
EV
$81M
Valuation Multiples
Start free trialMeta Biomed Financials
Meta Biomed reported last fiscal year revenue of $70M and EBITDA of $14M.
In the same fiscal year, Meta Biomed generated $37M in gross profit, $14M in EBITDA, and $8M in net income.
Meta Biomed P&L
In the most recent fiscal year, Meta Biomed reported revenue of $70M and EBITDA of $14M.
Meta Biomed is profitable as of last fiscal year, with gross margin of 52%, EBITDA margin of 20%, and net margin of 11%.
Financial data powered by Morningstar, Inc.
Meta Biomed Stock Performance
Meta Biomed has current market cap of $78M, and enterprise value of $81M.
Meta Biomed's stock price is $2.90.
Meta Biomed has an EPS (earnings per share) of $0.28.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $81M | $78M | -0.4% | — | — | — | $0.28 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMeta Biomed Valuation Multiples
Meta Biomed trades at 1.1x EV/Revenue multiple, and 5.6x EV/EBITDA.
Meta Biomed Financial Valuation Multiples
As of May 10, 2026, Meta Biomed has market cap of $78M and EV of $81M.
Meta Biomed has a P/E ratio of 10.3x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Meta Biomed Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Meta Biomed Margins & Growth Rates
In the most recent fiscal year, Meta Biomed reported gross margin of 52%, EBITDA margin of 20%, and net margin of 11%.
Meta Biomed Margins
Meta Biomed Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Meta Biomed Operational KPIs
Data powered by FactSet, Inc. and Morningstar, Inc.
Meta Biomed Competitors
Meta Biomed competitors include Cyclopharm, Senzime, FluoGuide, Optiscan Imaging, BioStem Technologies, Nexstim, Osang Healthcare, Medicalgorithmics, Applied BioCode and Sera Prognostics.
Most Meta Biomed public comparables operate across Medical Devices.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.4x | 3.2x | (6.7x) | (6.6x) | |||
| 6.3x | 5.4x | (6.6x) | (8.2x) | |||
| — | — | (11.0x) | (9.9x) | |||
| 98.1x | — | (16.0x) | — | |||
| 0.2x | 1.1x | 1.6x | — | |||
| 6.3x | 6.0x | 37.9x | 35.3x | |||
| 0.9x | — | 10.5x | — | |||
| 11.6x | 7.4x | (23.3x) | 2284.6x | |||
This data is available for Pro users. Sign up to see all Meta Biomed competitors and their valuation data. Start Free Trial | ||||||
Meta Biomed Investment Activity
Meta Biomed has invested in 1 company to date.
Latest investment by Meta Biomed was on March 17th 2026. Meta Biomed invested in LabInCube in their $10M Series B round (EV/Revenue multiple of ).
Latest Investments by Meta Biomed
| Description | LabInCube is a Seoul-based developer of inCube hydrogel materials for controlled drug release in implants and wound dressings. Formulations enable sustained delivery of antibiotics and growth factors, supporting tissue regeneration in orthopedic and dental applications through partnerships with Korean hospitals. | LabInCube is a Seoul-based developer of inCube hydrogel materials for controlled drug release in implants and wound dressings. Formulations enable sustained delivery of antibiotics and growth factors, supporting tissue regeneration in orthopedic and dental applications through partnerships with Korean hospitals. |
| HQ Country | ||
| HQ City | Cheongju | Cheongju |
| Deal Date | 17 Mar 2026 | 30 Dec 2025 |
| Round | Series B | Strategic investment |
| Raised | $10M | undisclosed |
| Investors | BNH Investment; JKP Partners; Meta Biomed; Union Investment Partners | Meta Biomed |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Meta Biomed investments and their VC round multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Meta Biomed
| When was Meta Biomed founded? | Meta Biomed was founded in 1999. |
| Where is Meta Biomed headquartered? | Meta Biomed is headquartered in South Korea. |
| Is Meta Biomed publicly listed? | Yes, Meta Biomed is a public company listed on Korea Exchange. |
| What is the stock symbol of Meta Biomed? | Meta Biomed trades under 059210 ticker. |
| When did Meta Biomed go public? | Meta Biomed went public in 2008. |
| Who are competitors of Meta Biomed? | Meta Biomed main competitors include Cyclopharm, Senzime, FluoGuide, Optiscan Imaging, BioStem Technologies, Nexstim, Osang Healthcare, Medicalgorithmics, Applied BioCode, Sera Prognostics. |
| What is the current market cap of Meta Biomed? | Meta Biomed's current market cap is $78M. |
| What is the current revenue of Meta Biomed? | Meta Biomed's last fiscal year revenue is $70M. |
| What is the current EV/Revenue multiple of Meta Biomed? | Current revenue multiple of Meta Biomed is 1.1x. |
| Is Meta Biomed profitable? | No, Meta Biomed is not profitable. |
| How many companies Meta Biomed has acquired to date? | Meta Biomed hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Meta Biomed has invested to date? | As of May 2026, Meta Biomed has invested in 1 company. |
| What was the last Meta Biomed investment? | On 17th March 2026 Meta Biomed invested in LabInCube, participating in a $10M Series B round, alongside BNH Investment, JKP Partners, and Union Investment Partners. |
| In what companies Meta Biomed invested in? | Meta Biomed invested in LabInCube. |
See public comps similar to Meta Biomed
Lists including Meta Biomed
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
